Objective-Vascular calcification significantly increases cardiovascular morbidity and mortality. We recently reported that the deficiency of cartilage oligomeric matrix protein (COMP) leads to vascular mineralization. We characterized the COMP-degrading metalloproteinase, a disintegrin and metalloproteinase with thrombospondin motifs-7 (ADAMTS-7).
V ascular calcification, namely aberrant deposition of calcium phosphate crystals in the vessel wall, contributes directly to cardiovascular morbidity and mortality among patients with chronic renal failure (CRF), atherosclerosis, and diabetes mellitus. 1 Compelling evidence has demonstrated that vascular calcification is a highly regulated form of biomineralization resembling bone modeling, rather than simply passive calcium deposition. 2 These processes involve coordinated regulation of inducers and inhibitors of calcification, but the precise mechanisms are poorly defined. [3] [4] [5] Metalloproteinases, including matrix metalloproteinase (MMP), a disintegrin and metalloproteinase or a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), play pivotal roles in both bone formation and arterial/cardiac remodeling by degrading matrix or nonmatrix substrates. [6] [7] [8] However, the importance of metalloproteinases in the pathogenesis of vascular calcification has not been recognized. A few animal studies have suggested that activation of MMPs leads to vascular calcification in chronic kidney disease, whereas broad-spectrum MMP inhibition or MMP-2/9 deficiency prevents CaCl 2 -induced aortic calcification and elastic fragmentation. [9] [10] [11] In addition, limited human studies have indicated that upregulation of MMP-2/9 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in diabetes mellitus and chronic kidney disease. 12, 13 Nevertheless, little is known about other areas of metalloproteinase involvement and how critical these proteinases are for vascular mineralization. Identifying the key metalloproteinase involved in calcification may uncover novel targets for future diagnosis and therapeutic interventions for end-stage renal disease, diabetes mellitus, and atherosclerosis.
Previously, we showed that cartilage oligomeric matrix protein (COMP), a vascular matricellular molecule, inhibits vascular smooth muscle calcification in vitro and in vivo by interfering with bone morphogenetic protein 2 expression and preventing osteochondrogenic transdifferentiation of vascular smooth muscle cells (VSMCs). 14 We observed similar COMP degradation in calcifying bovine and rat VSMCs and calcified human uraemic radial arteries. 14 These data suggest the importance of COMPdegrading proteinase in vascular calcification. Previously, we showed that the metalloproteinase ADAMTS-7 mediated degradation of COMP in injured vessels. 15, 16 Therefore, we wondered whether ADAMTS-7 regulates COMP degradation and contributes to VSMC calcification.
In this study, we used cellular and vascular mineralization models to investigate ADAMTS-7-mediating VSMC calcification via COMP degradation. We observed an early response of repression of miR-29a/b, which in turn facilitated VSMC calcification by targeting the 3′ untranslated region (UTR) of ADAMTS-7.
Materials and Methods
Animal care and use of 5⁄6 nephrectomy and CaCl 2 arterial injury model in male Sprague-Dawley rats were in accordance with institutional guidelines. Aortic ring organ calcification was induced as described previously. 14 Small interfering RNA against ADAMTS-7 was transfected in vitro by use of oligofectamine. The adenovirus for full-length rat ADAMTS-7 was constructed and 2.5 × 10 9 plaqueforming units of adenovirus-ADAMTS7 dissolved in 30% pluronic gel solution was periadventitially delivered to the rat carotid arteries 3 days before organ culture. 16 The microRNA (miRNA) expression was detected by use of the Exiqon miR assay kit (Denmark) according to the manufacturer's protocol. Double-stranded RNA oligos representing mature sequences that mimic endogenous pre-miR-29a/b and negative control mimic miRNA (GenePhama, Shanghai) were transfected into cells by use of Oligofectamine (Invitrogen). Similarly, single-stranded RNA oligos designed to inhibit endogenous miR-29a/b (anti-miR-29a/b) and negative control anti-miR (GenePhama) were transfected. For ex vivo studies, 10 μg of anti-miR-29a or anti-miR-29b, dissolved in 30% pluronic gel solution, was perivascularly delivered to rat carotid arteries 3 days before high-phosphate-induced aortic ring calcification. In CaCl 2 -induced regional calcification, 10 μg mimic or inhibitor of miR-29a/b, dissolved in 30% pluronic gel solution, was perivascularly delivered to rat carotid arteries right after CaCl 2 treatment and washing. Human radial artery specimens were collected from uraemic patients during arterial venous fistular operation and from patients with coronary heart disease who underwent coronary artery bypass grafting after getting the approval from the Local Research Ethics Committee. The procedures used were in accordance with the institutional guidelines. All the patients gave their informed consent for radial artery biopsy before surgery.
An expanded and detailed materials and methods section is available in the online-only Data Supplement.
Results

ADAMTS-7 Is Upregulated in Calcified VSMC and Vessels
To test whether ADAMTS-7 is involved in VSMC calcification, we first examined the expression of ADAMTS-7 in various calcification models. Clinical observations have suggested that medial artery calcification is a common complication in CRF. 17 We therefore examined ADAMTS-7 expression in radial artery specimens from uremic patients who underwent arterial venous fistular operation. The expression of ADAMTS-7 was greater in CRF radial arteries than in control arteries ( Figure 1A ). Furthermore, we analyzed ADAMTS-7 level in a rat CRF model. CRF rats showed a significant increase in the plasma level of blood urea nitrogen and creatinine (Table in the Figure 1B ). In addition, mineralization of VSMC was successfully induced in rat VSMCs with osteogenic media containing 2.6 mmol/L inorganic phosphate, as evidenced by Alizarin red S staining and increased calcium deposition ( Figure II in the online-only Data Supplement). High phosphate significantly induced ADAMTS-7 mRNA expression as early as 6 hours ( Figure  1C ), which remained elevated up to 12 days ( Figure 1E ). In accordance, the protein level of ADAMTS-7 was enhanced at 24 hours and increased up to 12 days ( Figure 1D 
ADAMTS-7 Mediates VSMC Calcification
Previously, we demonstrated that COMP was degraded in calcified vessels, and COMP prevents VSMCs calcification via inhibiting bone morphogenetic protein-2 (BMP-2) osteogenic signaling. 14 Here, we used gain-and loss-of-function study to test whether ADAMTS-7 mediates VSMC calcification by interfering in COMP degradation and BMP-2 signaling. As compared with adenovirus-green fluorescent protein infection, ADAMTS-7 overexpression by adenovirus infection (adenovirus-ADAMTS-7; Figure VIIA in the online-only Data Supplement) led to excess COMP degradation, paralleled by increased BMP-2, p-Smad1/5/8, and runt-related transcription factor 2/msh homeobox 2 levels, and then increased calcium deposition (Figure 2A Indeed, excess ADAMTS-7 exaggerated aortic ring calcification and its knockdown decreased the calcification (Figure 3 ).
ADAMTS-7 Is a Target of miR-29a/b in VSMCs
To explore the mechanism of ADAMTS-7 upregulation during vascular calcification, we first cloned a 1.45-kb promoter region flanking the 899 bp upstream to 550 bp downstream of the transcriptional starting site into the PGL3 luciferase vector. The vector was transfected into VSMCs, and transcriptional activity was monitored with high-phosphate stimulation. It is intriguing that high phosphate alone did not enhance ADAMTS-7 transcription, and further serial deletions of the promoter region produced no transcriptional activity ( Figure  IX in the online-only Data Supplement), which indicates a potential post-transcriptional regulatory mechanism.
MicroRNAsmiRNAs are, in general, 22-nt, noncoding small RNAs that ensure enhancement of mRNA degradation or suppression of protein translation by binding to the 3′ UTR of their target mRNA. Use of the bioinformatics databases TargetScan, PITA, MicroCosom, and PicTar predicted that ADAMTS-7 is a potential target of miR-29a/b. Sequence alignment of miR-29a or miR-29b sites in the 3′ UTR of ADAMTS-7 showed high conservation among human, mouse, rat, and canine ( Figure 4A ). To test whether miR-29a/b directly regulates ADAMTS-7, we constructed luciferase reporters containing the wild-type 3′ UTR of ADAMTS-7 or with deletion or mutation of the predicted miR-29 binding seed region ( Figure 4B ). VSMCs were cotransfected with miR-29a/b mimic or negative control molecules. The miR-29a/b mimic significantly inhibited the reporter luciferase activity, by ≈40%, as compared with the control molecule. In contrast, deletion or mutation of the predicted miR-29a/b binding site within the 3′ UTR of ADAMTS-7 abolished miR-29a/b inhibition. In addition, the miR-29a/b mimic markedly repressed ADAMTS-7 mRNA and protein expression in VSMCs, whereas anti-miR-29a/b increased the levels ( Figure 4C and 4D) . Therefore, miR-29a/b can negatively regulate ADAMTS-7 mRNA by targeting its 3′ UTR.
MiR-29a and miR-29b Are Downregulated in Calcifying VSMCs
Because ADAMTS-7 was negatively regulated by miR-29a/b and its expression was enhanced during vascular calcification, we wondered whether miR-29a/b level was altered during the process. First, we analyzed miR-29a/b expression by quantitative reverse transcriptase-polymerase chain reaction. High phosphate inhibited miR-29a/b as early as 1 hour after stimulation; the repression was sustained up to day 6 and returned to normal on day 9 ( Figure 5A and 5B) . Second, because miRNAs targeting mRNA depend on the association of the miRNA/mRNA complex with Ago proteins to form microRNAinduced silencing complex, we investigated the expression of miR-29a/b in Ago2-immunoprecipitated microRNA-induced silencing complex. High phosphate significantly ameliorated miR-29a/b level at 3 and 12 hours as compared with that at time 0, but Ago2 protein expression was not altered ( Figure 5C ; Figure To further explore the potential mechanism of miR-29 repression during VSMC calcification, we first detected nuclear factor (NF)-κB activation within 1 hour after highphosphate stimulation. Phosphorylation of p65 was increased and IκBα protein level decreased as early as 10 minutes after high-phosphate stimulation ( Figure XIIA 
MiR-29a/b Inhibits VSMC Calcification by Suppressing ADAMTS-7
To explore whether miR-29a/b is truly involved in vascular calcification, we transfected VSMCs with mimic miR-29a/b before high-phosphate stimulation. The overexpression of miR-29a/b inhibited high-phosphate-induced ADAMTS-7 expression, COMP degradation, and BMP-2 signaling activation at day 6 ( Figure XIIIA (Figure 6A and 6B) . These data suggest that miR-29a/b actively participates in modulating vascular calcification. It is intriguing that specific knockdown of ADAMTS-7 with small interfering RNA but not scramble small interfering RNA circumvented anti-miR-29a/b-enhanced VSMC mineralization with high-phosphate stimulation ( Figure 6C ). Therefore, miR-29a/b may inhibit VSMC calcification by suppressing ADAMTS-7 expression. The repression of miR-29a/b by risk factors such as high phosphate led to enhanced ADAMTS-7 expression or COMP degradation, upregulated BMP-2 osteogenic signaling in VSMCs and, ultimately, accelerated vascular calcification.
Discussion
Researchers have embraced the concept that vascular calcification is a multifaceted and actively regulated process rather than simple passive calcium deposition and degeneration. Various molecular mechanisms have been elucidated, including abnormal calcium or phosphate metabolism, osteogenic reprogramming of VSMCs, apoptosis, oxidative stress and inflammation, and loss of inhibitors of mineralization. [18] [19] [20] [21] However, the understanding of vascular mineralization is far from ideal, and an effective preventive or therapeutic strategy for vascular calcification in atherosclerosis, CRF, and diabetes mellitus is still lacking. Here we reveal a novel underlying mechanism in vascular calcification that involves the miR-29/ ADAMTS-7/COMP axis.
ADAMTS comprise a family of 19 secreted enzymes that have been linked to various physiological processes, including development, angiogenesis, and coagulation. Aberrant expression or function of ADAMTS members have been implicated in many disease states such as arthritis, cancer, thrombocytopenic purpura, and cardiovascular disease. [22] [23] [24] Recently, 2 independent genome-wide association studies identified ADAMTS-7 as a novel locus for coronary atherosclerosis. 25, 26 We previously demonstrated that ADAMTS-7, through COMP processing, mediates the migration of VSMCs and subsequent neointima formation after vascular injury. 16 COMP is a 550-kD pentameric glycoprotein necessary for maintaining the VSMC contractile phenotype. 27 COMP deficiency facilitates osteogenic transdifferentiation of VSMCs, because the deficient COMP is incapable to inhibit the interacting BMP-2. 14 BMP-2 promotes vascular calcification by its increased phosphate uptake and by modulating an osteogenic phenotype in smooth muscle cells by binding to the receptor, BMP receptor 1 or BMP receptor 2, which in turn phosphorylates the regulatory Smad1/5/8 and upregulates downstream key osteogenic transcription factors, including runtrelated transcription factor 2 and msh homeobox 2. Of note, we observed COMP degradation in various vascular mineralization models. 14 In the current study, we further demonstrated that the interference of ADAMTS-7 in calcifying VSMCs or vessels led to subsequent change in COMP degradation in parallel with the alteration of BMP-2, p-Smad1/5/8, and runtrelated transcription factor 2/msh homeobox 2 levels. These observations reinforce the importance of a counterbalance between COMP and BMP-2 during vascular calcification. Interfering in ADAMTS-7 or COMP processing may shed light on preventing VSMC calcification. Of note, purified COMP has been reported to be digested in vitro by several MMPs at higher concentrations than those in physiological or pathological conditions. 28 Accumulating evidence also suggests the importance of MMP-2, -9, and -12 during the etiology of vascular calcification by degrading elastin or nonmatrix substrates such as transforming growth factor β. 9, 29 Nevertheless, we previously demonstrated that 4 C-terminal thrombospondin repeats of ADAMTS-7 are required and sufficient for COMP binding and degrading, which are lacking in the above-mentioned MMPs. 15 To date, COMP is the only identified substrate of ADAMTS-7 in blood vessels. 15, 16 However, we cannot exclude the existence of other potential substrates of ADAMTS-7 in smooth muscle cells or a COMP-independent mechanism of ADAMTS-7 in vascular calcification. Previously, we showed that ADAMTS-12, a homology of ADAMTS-7, can also bind and process COMP in vitro. 30 Whether ADAMTS-12 contributes to vascular calcification remains elusive. Considering the complexity of the biological function of individual metalloproteinases, continued research is required to unravel the key enzyme(s) relevant in vascular calcification.
Here, we identified the novel regulator miR-29 in VSMC mineralization, which is downregulated during calcification and epigenetically targets ADAMTS-7 in VSMCs. The exclusive downregulation of miR-29a/b within current vascular calcification models suggests that it may act as a modulator during the process. Indeed, our data indicated that interference of miR-29a/b led to subsequent alteration in the expression of ADAMTS-7, BMP-2, p-Smad1/5/8, and runtrelated transcription factor 2/msh homeobox 2 and COMP degradation to ultimately affect vascular calcification. These data highlight the importance of the miR-29/ADAMTS-7/ COMP axis during the process of calcification. Compelling evidence suggests that the miR-29 family members directly target multiple genes, although their functional relevance in various disease states may not be identical. The miR-29 family may be pivotal for controlling osteoblast and osteoclast differentiation and function during bone remodeling by targeting osteonectin and Wnt signaling. 31, 32 In addition, miR-29 may be a critical regulator of extracellular matrix factors including elastin, collagen, laminin, gamma 1, fibronectin, BMP-1, ADAM12, and NFKB inhibitor interacting Raslike 2, which are closely related to trabecular meshwork reassembling, cardiac/pulmonary/liver fibrosis, or aortic aneurysm. [33] [34] [35] Recently, RNA sequencing of a stable miR-29-transfected C2C12 cell line revealed ADAMTS-7 as 1 of the potential targets. 36 In addition, miR-29 may affect cellular senescence or aging by regulating B-myc or p53. 37, 38 Our current study has extended our understanding of miR-29 in matrix turnover by providing evidence that by negatively regulating ADAMTS-7, miR-29 indirectly affects COMP degradation, thereby influencing vascular calcification. Because miR-29 is known to target many other genes, particularly those from the fibrotic/extracellular matrix pathway, decreased miR-29 level in the context of calcific stimulus would possibly lead not only to vessel calcification but also to vascular thickening and fibrosis. Recently, miR-125 was also reported to regulate VSMC calcification by targeting the osteoblast transcription factor osterix. 39 An in-depth understanding of the roles of these regulatory RNAs in VSMC mineralization will be critical for developing new therapies for vascular calcification.
In the current study, miR-29a/b level was repressed in highphosphate-induced calcifying VSMCs or blood vessels with chronic kidney disease, which agreed with a previous report of miR-29a/b suppression in muscles from mice with chronic kidney disease. 40 Decreased aortic expression of miR-29b was also reported in angiotensin II-and pancreatic elastaseinduced murine models of abdominal aortic aneurysm. 41, 42 In contrast, markedly upregulated miR-29 was suggested in senescent VSMCs, in aging mice or in Marfan syndrome. 38, 41 Therefore, different mechanisms are involved in the regulation of miR-29 under various states. The mechanism accounting for downregulation of miR-29a/b during calcification is not yet determined. However, miR-29a/b is transcriptionally suppressed by transforming growth factor β, c-Myc, hedgehog, and NF-κB. 43, 44 Here, we have shown that NF-κB activation mediated high-phosphate-induced miR-29a/b repression, which agrees with our previous observation that mitochondrial NF-κB activation mediated by reactive oxygen species facilitated high-phosphate-induced VSMC calcification. 45 In addition, the in vivo model we used in the current study involved complex mechanisms, including high phosphate, inflammation, oxidative stress, and apoptosis, so the precise mechanism of miR-29a/b inhibition of vascular calcification in vivo needs to be further explored.
In summary, we have indicated a novel regulatory role of the miR-29/ADAMTS-7/COMP axis during vascular calcification in vitro and in vivo. The axis may be a novel therapeutic target for vascular calcification. 
